UPDATE: Piper Jaffray Downgrades Hansen Medical to Neutral on Continued Sales Uncertainty

By: Benzinga
In a report published Thursday, Piper Jaffray analyst Brooks E. West downgraded the rating on Hansen Medical (NASDAQ: HNSN ) from Overweight to Neutral, and lowered the price target from $3.00 to $1.50. In the report, West noted, “HNSN continues to face challenges commercializing the Magellan vascular system, with only
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.